Recommended quality measures for health-system pharmacy: 2019 update from the Pharmacy Accountability Measures Work Group

Andrawis, Mary; Ellison, L T C Christopher; Riddle, Steve; Mahan, Kurt Charles; Collins, Curtis D.; Brummond, Philip; Carmichael, Jannet M.

doi:10.1093/ajhp/zxz069

Cited by 17 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,49,84,85 Opioid stewardship encompasses an interprofessional, multidisciplinary, and holistic approach to Furthermore, in order to benchmark opioid stewardship program success and ensure the service aligns with the Quadruple Aim, 88 pharmacists should actively participate in the development and monitoring of opioid-related quality and performance measures. 83 Evidence is insufficient for the routine use of opioids for chronic noncancer pain (CNCP), though there is good-quality evidence of a dose-dependent risk for serious harm. 89 When opioids are started early for pain management and at high doses, the likelihood for opioid persistence increases significantly, 90,91 In the last few years, numerous stakeholders and policymakers have enacted rules and regulations that limit the duration of opioid prescriptions for acute pain or initial prescriptions, in order to curb opioid-related harms.…”

Section: Overdose Education and Naloxone Distributionmentioning

confidence: 99%

“…Although these programs have different approaches to stewardship, the most common activities include (in rank order): clinician education and guideline development; routine PDMP inquiries; prioritization of nonpharmacologic and nonopioid pain management strategies; and opioid diversion detection. Pharmacists are becoming increasingly accountable for opioid‐related quality measures 83 . Figure 3 describes the most common pharmacist activities in opioid stewardship programs.…”

Section: Opioid Stewardshipmentioning

confidence: 99%

See 1 more Smart Citation

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Coon

Hill

Hutchison³

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence‐based opioid stewardship and harm reduction practices, contribute to the medical management of opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far‐reaching pharmacist‐led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence‐based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high‐level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist‐led clinical services, so that resources can be allocated effectively.

show abstract

Section: Overdose Education and Naloxone Distributionmentioning

confidence: 99%

Section: Opioid Stewardshipmentioning

confidence: 99%

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Coon

Hill

Hutchison³

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

“…Thielemeier and Tu identified several strategies for pharmacists to partner with their physician colleagues to help boost measure ratings in MIPS 22 . The American Society of Health‐System Pharmacists (ASHP) published a call for pharmacists to take up leadership roles in quality improvement and the ASHP Pharmacy Accountability Measures workgroup identified 28 different quality measures that can capture the quality of pharmacist provided services in both inpatient and outpatient settings 23,24 …”

Section: The Pharmacist's Role In Qualitymentioning

confidence: 99%

Measuring health care quality: Implications, threats, and opportunities for clinical pharmacists

Ramachandran

Galdo

Urick

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

The Patient Protection and Affordable Care Act of 2010 has helped usher in an era of focus on health care quality and quality improvement. Since then, a variety of programs has driven quality improvement throughout the health care system using a combination of incentives and penalties. Many studies have demonstrated the value of integrating clinical pharmacist services into interdisciplinary models of care for the purpose of moving the needle on performance measures. The implementation of quality‐linked reimbursement programs has the greatest potential to meaningfully improve quality of care and reduce costs. However, the benefits of quality measures are dependent on their implementation into measurement systems and their application into clinical practice. Common threats to quality measurement in pharmacy practice may arise due to misapplication of health plan‐related measures to evaluate pharmacy services. Additionally, the core concepts related to novel reimbursement models have not adequately percolated into the formal education of practicing pharmacists. Therefore, the goal of this article is to help educate and raise awareness about the current quality landscape and present opportunities and directions for pharmacists to demonstrate their value in interdisciplinary health care teams. This article is broadly divided into four sections—first, we provide an introduction to quality measurement and its application to clinical pharmacists. Second, we elaborate on the development and endorsement of quality measures and measurement systems. Third, we present clinical scenarios of patient care—set in inpatient, ambulatory care, and community practice settings—that engage pharmacists in the context of quality measurement and evaluate the implications, threats, and opportunities for clinical pharmacists in each of these scenarios. Finally, we present recommendations for future advocacy, measurement, and leadership for pharmacist involvement in the quality landscape.

show abstract

“…[15][16][17][18][19] The American Society of Health-System Pharmacists has created quality measures for pharmacy focused largely on primary care disease states. 20 However, quality measures for specialty pharmacy and newer targeted oncolytic therapies, including TKIs, are largely lacking. Although adherence to TKIs in NSCLC is reported to be greater than 95%, 21,22 even a small decrease in adherence can negatively impact outcomes.…”

Section: Introductionmentioning

confidence: 99%

Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative

Crothers

Shah

Kim

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Tyrosine kinase inhibitors, commonly prescribed for non-small cell lung cancer, are efficacious but pose safety risks that can diminish quality of life. Quality measures to ensure appropriate utilization and monitoring of tyrosine kinase inhibitors are needed to reduce unnecessary healthcare costs and maximize therapeutic benefit. With integrated clinical and pharmaceutical care services, a health-system specialty pharmacy is the ideal setting for quality measures development. Purpose The purpose of this initiative was to develop a tool to assess quality in the utilization of tyrosine kinase inhibitors in non-small cell lung cancer by engaging multiple key stakeholder perspectives to identify the fundamental elements of high-quality clinical and specialty pharmacy care. Summary Quality measures for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer were developed by conducting package insert, guideline, and literature review followed by integrating feedback from key stakeholder groups through individual conversations and a structured assessment. The finalized guide assesses safety, efficacy, persistence, and patient-reported outcomes using defined clinical and specialty pharmacy measures. Most stakeholders agreed that the proposed measures were relevant as well as accurate and expressed support for implementation. Conclusions The proposed tool provides a framework for specialty pharmacies to deliver quality care in the use of tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Further work is needed to implement and validate this tool.

show abstract

Recommended quality measures for health-system pharmacy: 2019 update from the Pharmacy Accountability Measures Work Group

Cited by 17 publications

References 15 publications

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Measuring health care quality: Implications, threats, and opportunities for clinical pharmacists

Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative

Contact Info

Product

Resources

About